U-LABA/ICS Effects on Exercise Performance, Indacaterol

Launched by MORTEN HOSTRUP, PHD · Sep 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called indacaterol, combined with mometasone furoate, affects exercise performance in physically active adults. The researchers want to see if using this medication can help improve how well people can exercise after taking it. The trial is currently looking for participants aged 18 to 39 who are very active, exercising more than five hours a week and have a high level of oxygen consumption during exercise.

To be eligible for the study, you should not have severe asthma or certain heart conditions, and you should not be pregnant, a smoker, or have donated blood in the last three months. If you qualify and decide to participate, you can expect to undergo some tests to assess your exercise performance and overall health. This trial is a great opportunity for those who are active and want to contribute to research that could help improve exercise capabilities for other individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-39
• • Physically active \> 5 h weekly
• • Maximal oxygen consumption classified as high or very high
• Exclusion Criteria:
• • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
• • ECG abnormality
• • ACQ score \> 1.5
• • Severe bronchial hyperreactivity as determined by mannitol test
• • FEV1/FVC ratio \< 0.7 determined with spirometry
• • Chronic illness determined to be a potential risk for participant during study
• • In chronic treatment with medication that may interfere with study results
• • Pregnancy
• • Smoker
• • Blood donation during the past 3 months